The FDA also recommends examining hard clinical endpoints such hepatic decompensations, transplant free survival, and all-cause mortality, although these results are not necessarily needed prior to drug approval given the long length of follow up potentially required
This will include pathways for prescribing as well as referring into a wraparound offer
2A R antagonists can improve motor dysfunction in patients with PD as monotherapy or in combination with L-DOPA and other antiparkinsonian drugs (Table 1) [57,58]
Neves AL, Coelho J, Couto L, Leite-Moreira A, Roncon-Albuquerque R (2013) Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk
It does not mean guaranteed approval, guaranteed prescription issuance, or guaranteed delivery within any specific window